SEC Form 4 · accession 0001242615-26-000002
ARROWHEAD PHARMACEUTICALS, INC. · ARWR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adeoye Y Olukotun
Director
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 5:25 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000879407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 18, 2026 | S | 2,000 | $86.96 | D | 31,600 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.